Dr Nicolas Girard speaks to ecancer at ESMO 2024 about the patient reported outcome results from the LUMINOSITY trial. This trial evaluated telisotuzumab vedotin in patients with c-Met protein overexpressing, EGFR wildtype, non-squamous non-small cell lung cancer.
Lung cancer/treatment-related symptoms and impact on function and quality of life were evaluated using the EORTC quality of life questionnaires.
Dr Girard reports that patients treated with telisotuzumab vedotin reported improvement or maintenance in most patient-reported outcomes evaluated.